At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02575 XUANZHUBIO-B
Market Closed 03-27 16:08:18
35.100
-1.020
-2.82%
High37.800
Low35.100
Vol666.00K
Open36.120
D1 Closing36.120
Amplitude7.48%
Mkt Cap18.18B
Tradable Cap5.64B
Total Shares518.00M
T/O23.98M
T/O Rate0.41%
Tradable Shares160.70M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
XuanZhuBio-B Shares Surge Over 18% Following Publication of Bireociclib Phase III Trial Results in Top Medical Journal
XUANZHUBIO-B (02575) Final Analysis of Phase III Trial for Bireociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer Published in Top-Tier Journal JAMA Oncology
Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis
Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.